CONNECT BIOPHARMACEUTICALS
Connect Biopharmaceuticals is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. They identify and advance our drug candidates through in-house discovery and in-licensing while leveraging qualified CROs for further development. The company successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator for t... he treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis. Connect Biopharmaceuticals currently conducting two phases 2 clinical studies in patients with ulcerative colitis and Crohn's disease with their lead drug candidate CBP-307. It also concluding a phase 1 study of our second drug candidate CBP-201 in healthy subjects, with a phase 1b study in atopic dermatitis patients expected to commence in Q1, 2019. Connect Biopharmaceuticals was founded in 2012 and is headquartered in Taichang, China.
CONNECT BIOPHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Health Care Medical Therapeutics
Founded:
2012-01-01
Address:
Taicang, Hebei, China
Country:
China
Website Url:
http://www.connectbiopharm.com
Total Employee:
1+
Status:
Active
Contact:
0512-53577866
Email Addresses:
[email protected]
Total Funding:
195 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Asahi Genomics
Asahi Genomics is into development of clinical testing technology, business related to overcoming diseases and improving / promoting health.
Current Advisors List

![]()
Current Employees Featured




Founder

Stock Details
Investors List
![]()
Qiming Venture Partners
Qiming Venture Partners investment in Series C - Connect Biopharmaceuticals
![]()
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Connect Biopharmaceuticals
![]()
RA Capital Management
RA Capital Management investment in Series C - Connect Biopharmaceuticals
![]()
Boxer Capital
Boxer Capital investment in Series C - Connect Biopharmaceuticals
![]()
Lilly Asia Ventures
Lilly Asia Ventures investment in Series C - Connect Biopharmaceuticals
![]()
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Connect Biopharmaceuticals
![]()
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Connect Biopharmaceuticals
![]()
Cowin Capital
Cowin Capital investment in Series B - Connect Biopharmaceuticals
Advantech Capital
Advantech Capital investment in Series B - Connect Biopharmaceuticals
![]()
Cowin Capital
Cowin Capital investment in Series A - Connect Biopharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-22 | Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer |
Official Site Inspections
http://www.connectbiopharm.com Semrush global rank: 4.88 M Semrush visits lastest month: 1.8 K
- Host name: 104.21.38.220
- IP address: 104.21.38.220
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
